Nick Leschly, MBA
Leschly has served as the chief executive officer of bluebird bio (BLUE), a gene therapy company focused on treating, and hopefully curing, a broad range of serious genetic diseases, since 2010. Formerly, he was a partner and founding member of Third Rock Ventures in 2007. Leschly has played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals (AGIO) and Edimer Pharmaceuticals. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. He received his Bachelor of Science in Molecular Biology from Princeton University and his Master of Business Administration from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic.